External imaging of CCND1 cancer gene activity in experimental human breast cancer xenografts with99mTc-peptide-peptide nucleic acid-peptide chimeras

Journal of Nuclear Medicine

Volumn 45, Issue 12, 2004, Pages 2070-2082

  Tian, Xiaobing ^a   Aruva, Mohan R ^b   Qin, Wenyi ^c   Zhu, Weizhu ^c   Duffy, Kevin T ^a   Sauter, Edward R ^c   Thakur, Mathew L ^b,d   Wickstrom, Eric ^a,d  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c University of Missouri   (United States)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Antisense; Oligonucleotides; Oncogenes; Peptides; Radionuclides; Scintigraphy

Indexed keywords

CYCLIN D1; MESSENGER RNA; PEPTIDE NUCLEIC ACID; SOMATOMEDIN C; TECHNETIUM 99M; CCND2 PROTEIN, HUMAN; CYCLINE; DIAGNOSTIC AGENT; TECHNETIUM DERIVATIVE;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CHIMERA; CONTROLLED STUDY; DNA HYBRIDIZATION; FEMALE; FLUORESCENCE MICROSCOPY; GENE ACTIVITY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOLID PHASE SYNTHESIS; TUMOR GENE; TUMOR XENOGRAFT; ANIMAL; BREAST TUMOR; CELL CULTURE; GENETICS; METABOLISM; NUDE MOUSE; SCINTISCANNING; XENOGRAFT;

ANIMALS; BREAST NEOPLASMS; CYCLINS; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MICE; MICE, NUDE; MICROSCOPY, FLUORESCENCE; PEPTIDE NUCLEIC ACIDS; TECHNETIUM COMPOUNDS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 12344264096     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Fahy BN, Bold RJ, Schneider PD, Khatri V, Goodnight JE Jr. Cost-benefit analysis of biopsy methods for suspicious mammographic lesions. Arch Surg. 2001;136:990-994.
2. Diekmann F, Diekmann S, Bollow M, et al. Evaluation of a wavelet-based computer-assisted detection system for identifying microcalcifications in digital full-field mammography. Acta Radiol. 2004;45:136-141.
3. Pappo I, Horne T, Weissberg D, Wasserman I, Orda R. The usefulness of MIBI scanning to detect underlying carcinoma in women with acute mastitis. Breast J. 2000;6:126-129.
4. 99mTc sestamibi scintimammography in patients with non-palpable, mammographically detected, suspicious, breast lesions. Nucl Med Commun. 2002;23:1073-1078.
5. Ma XJ, Salunga R, Tuggle JT, et al. Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci USA. 2003;100:5974-5979.
6. Surmacz E. Growth factor receptors as therapeutic targets: strategies to inhibit the insulin-like growth factor I receptor. Oncogene. 2003;22:6589-6597.
7. Berns EM, Klijn JG, van Staveren IL, Portengen H, Noordegraaf E, Foekens JA. Prevalence of amplification of the oncogenes c-myc, HER2/neu, and int-2 in one thousand human breast tumours: correlation with steroid receptors. Eur J Cancer. 1992;28:697-700.
8. Martin KJ, Kritzman BM, Price LM, et al. Linking gene expression patterns to therapeutic groups in breast cancer. Cancer Res. 2000;60:2232-2238.
9. Andrews DW, Resnicoff M, Flanders AE, et al. Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type I receptor in malignant astrocytomas. J Clin Oncol. 2001;19:2189-2200.
10. Carroll JS, Prall OW, Musgrove EA, Sutherland RL. A pure estrogen antagonist inhibits cyclin E-Cdk2 activity in MCF-7 breast cancer cells and induces accumulation of p130-E2F4 complexes characteristic of quiescence. J Biol Chem. 2000;275:38221-38229.
11. Wickstrom E, Tyson FL. Differential oligonucleotide activity in cell culture versus mouse models. In: Chadwick D, Cardew G, eds. Oligonucleotides as Therapeutic Agents. Vol 209. London, U.K.: Wiley; 1997:124-137.
12. Wickstrom EL, Bacon TA, Gonzalez A, Freeman DL, Lyman GH, Wickstrom E. Human promyelocytic leukemia HL-60 cell proliferation and c-myc protein expression are inhibited by an antisense pentadecadeoxynucleotide targeted against c-myc mRNA. Proc Natl Acad Sci USA. 1988;85:1028-1032.
13. Wickstrom E, Bacon TA, Wickstrom EL. Down-regulation of c-MYC antigen expression in lymphocytes of Emu-c-myc transgenic mice treated with anti-c-myc DNA methylphosphonates. Cancer Res. 1992;52:6741-6745.
14. Smith JB, Wickstrom E. Antisense c-myc and immunostimulatory oligonucleotide inhibition of tumorigenesis in a murine B-cell lymphoma transplant model. J Natl Cancer Inst. 1998;90:1146-1154.
15. Bishop MR, Jackson JD, Tarantolo SR, et al. Ex vivo treatment of bone marrow with phosphorothioate oligonucleotide OL(1)p53 for autologous transplantation in acute myelogenous leukemia and myelodysplastic syndrome. J Hematother. 1997;6:441-446.
16. 99mTc-Labeled vasoactive intestinal peptide receptor agonist: functional studies. J Nucl Med. 1999;40:352-360.
17. 99mTc-labeled fibrin alpha-chain peptide. J Nucl Med. 2000;41:161-168.
18. 99mTc-Labeled vasoactive intestinal peptide analog for rapid localization of tumors in humans. J Nucl Med. 2000;41:107-110.
19. Stalteri MA, Mather SJ. Hybridization and cell uptake studies with radiolabelled antisense oligonucleotides. Nucl Med Commun. 2001;22:1171-1179.
20. Dewanjee MK, Ghafouripour AK, Kapadvanjwala M, et al. Noninvasive imaging of c-myc oncogene messenger RNA with indium-111-antisense probes in a mammary tumor-bearing mouse model. J Nucl Med. 1994;35:1054-1063.
21. 68Ga-Labeled oligonucleotides for in vivo imaging with PET. J Nucl Med. 2004;45:347-355.
22. Good L, Nielsen PE. Progress in developing PNA as a gene-targeted drug. Antisense Nucleic Acid Drug Dev. 1997;7:431-437.
23. 99mTc-peptide-peptide nucleic acid probes for imaging oncogene mRNAs in tumours. Nucl Med Commun. 2003;24:857-863.
24. Gray GD, Basu S, Wickstrom E. Transformed and immortalized cellular uptake of oligodeoxynucleoside phosphorothioates, 3′-alkylamino oligodeoxynucleotides, 2′-O-methyl oligoribonucleotides, oligodeoxynucleoside methylphosphonates, and peptide nucleic acids. Biochem Pharmacol. 1997;53:1465-1476.
25. Summerton J, Weller D. Morpholino antisense oligomers: design, preparation, and properties. Antisense Nucleic Acid Drug Dev. 1997;7:187-195.
26. Egholm M, Buchardt O, Christensen L, et al. PNA hybridizes to complementary oligonucleotides obeying the Watson-Crick hydrogen-bonding rules. Nature. 1993;365:566-568.
27. Urtishak KA, Choob M, Tian X, et al. Targeted gene knockdown in zebrafish using negatively charged peptide nucleic acid mimics. Dev Dyn. 2003;228:405-413.
28. Liu G, He J, Dou S, et al. Pretargeting in tumored mice with radiolabeled morpholino oligomer showing low kidney uptake. Eur J Nucl Med Mol Imaging. 2004;31:417-424.
29. 99mTc-antisense DNAs without entrapment. Mol Imaging Biol. 2003;5:240-247.
30. Soomets U, Hallbrink M, Langel U. Antisense properties of peptide nucleic acids. Front Biosci. 1999;4:D782-D786.
31. Basu S, Wickstrom E. Synthesis and characterization of a peptide nucleic acid conjugated to a D-peptide analog of insulin-like growth factor 1 for increased cellular uptake. Bioconjug Chem. 1997;8:481-488.
32. Pietrzkowski Z, Wernicke D, Porcu P, Jameson BA, Baserga R. Inhibition of cellular proliferation by peptide analogues of insulin-like growth factor 1. Cancer Res. 1992;52:6447-6451.
33. Boffa LC, Scarfi S, Mariani MR, et al. Dihydrotestosterone as a selective cellular/nuclear localization vector for anti-gene peptide nucleic acid in prostatic carcinoma cells. Cancer Res. 2000;60:2258-2262.
34. Tian X, Wickstrom E. Continuous solid-phase synthesis and disulfide cyclization of peptide-PNA-peptide chimeras. Org Lett. 2002;4:4013-4016.
35. Bartucci M, Morelli C, Mauro L, Ando S, Surmacz E. Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells. Cancer Res. 2001;61:6747-6754.
36. Bièche I, Olivi M, Nogues C, Vidaud M, Lidereau R. Prognostic value of CCND1 gene status in sporadic breast tumours, as determined by real-time quantitative PCR assays. Br J Cancer. 2002;86:580-586.
37. Bièche I, Laurendeau I, Tozlu S, et al. Quantitation of MYC gene expression in sporadic breast tumors with a real-time reverse transcription-PCR assay. Cancer Res. 1999;59:2759-2765.
38. Tian X, Aruva MR, Rao PS, et al. Imaging oncogene expression. Ann NY Acad Sci. 2003;1002:165-188.
39. Jain RK. The next frontier of molecular medicine: delivery of therapeutics. Nat Med. 1998;4:655-657.
40. Hedberg Y, Davoodi E, Roos G, Ljungberg B, Landberg G. Cyclin-D1 expression in human renal-cell carcinoma. Int J Cancer. 1999;84:268-272.